

Virtual Reality Exposure Therapy: Advancements in Treating Phobias in Digital Age- A Systematic Review

Meera. M^{*1}, Seethalakshmy.A²

¹Assistant Professor, Department of Psychology, Rathinam College of Arts and Science, Coimbatore, India, meera.psy@rathinam.in

²Head and Assistant Professor, Department of Psychology, Rathinam College of Arts and Science, Coimbatore, India, hod.psy@rathinam.in

*Corresponding Author

This article is part of a special issue dedicated to the International Conference on Emerging Technologies in Multidisciplinary Fields (ICETMF25), 8–9 July 2025, organized by Mazoon College, Muscat, Oman.

Received: 24/07/2025, Revised: 25/07/2025, Accepted: 24/08/2025, Published: 03/09/2025

Abstract

What if confronting your deepest fears could happen inside a headset rather than a therapist's office? Virtual Reality Exposure Therapy (VRET) offers a scalable, immersive alternative to traditional treatments for anxiety and phobia-related disorders by integrating psychological science with digital simulation technologies. This systematic review evaluates the clinical efficacy, technological progression, and implementation challenges of VRET, with a focus on its application to conditions such as acrophobia, social anxiety, and agoraphobia. The study contributes to the broader discourse on emerging technologies in multidisciplinary domains, particularly the convergence of mental health, computing, and behavioural science. Following PRISMA guidelines, a comprehensive search was conducted across PubMed, PsycINFO, Scopus, and Web of Science for empirical studies published between 2005 and 2025. Thirty-eight studies, primarily randomized controlled trials, met the inclusion criteria. Quantitative synthesis revealed significant reductions in symptom severity (Cohen's $d = 0.60-1.15$), with VRET outcomes often comparable to or exceeding those of traditional exposure therapies. Additional benefits included high patient engagement, lower dropout rates, and enhanced treatment accessibility. However, the review also identified considerable variability in VR platform types, exposure protocols, and outcome measures. Methodological constraints such as small sample sizes, inconsistent follow-up durations, and insufficient blinding procedures limited generalizability. Ethical issues including data privacy, cybersickness, and potential algorithmic bias warrant further scrutiny. This review highlights VRET's transformative role in digital mental health interventions and emphasizes the need for interdisciplinary collaboration. Future research should focus on AI-enabled personalization, standardized frameworks, and scalable, cost-effective delivery models to ensure equitable access.

Keywords: Virtual Reality Exposure Therapy (VRET), Phobia Treatment, Digital Mental Health, Emerging Technologies, Interdisciplinary Innovation

1. Introduction

Anxiety and phobia-related disorders are among the most prevalent and disabling mental health conditions worldwide, contributing significantly to individual distress and societal burden (Kessler et al., 2005; WHO, 2022). Cognitive-behavioral therapy (CBT), particularly exposure-based approaches, remains the gold standard. However, its application is often hindered by limited accessibility, high attrition rates, and logistical challenges in real-world exposure scenarios (Opris et al., 2012; Emmelkamp et al., 2020). Virtual Reality Exposure Therapy (VRET) has emerged as a promising digital intervention, offering controlled, repeatable, and customizable exposure experiences in simulated environments. VRET enables safe, structured exposure to scenarios such as heights, public speaking, or open spaces (Maples-Keller et al., 2017; Freeman et al., 2018). Early evidence supports its effectiveness and patient engagement potential (Carl et al., 2019). However, inconsistencies across VR platforms, therapeutic protocols, and outcome metrics hinder comparability and generalizability. Ethical



challenges, including cybersickness, data privacy, inequitable access, and algorithmic bias, further complicate large-scale implementation (Parsons & Rizzo, 2008; Wiederhold & Wiederhold, 2020). While individual studies have assessed VRET's efficacy, no comprehensive synthesis has yet evaluated its clinical performance, technological diversity, and ethical feasibility in an integrated manner. This systematic review addresses the question: To what extent is VRET clinically effective, technologically viable, and ethically implementable for treating anxiety and phobia-related disorders? The objectives are to (1) evaluate clinical outcomes of VRET interventions, (2) examine technological and therapeutic variations, and (3) identify implementation barriers. Following PRISMA guidelines, empirical studies published between 2005 and 2025 were systematically reviewed across PubMed, PsycINFO, Scopus, and Web of Science. Uniquely, this is the first systematic review to examine VRET research up to 2025 through a comprehensive ethical-techno-clinical lens, bridging gaps across disciplines and time.

2. Related Work

Virtual Reality Exposure Therapy (VRET) has gained increasing attention as an innovative treatment for anxiety and phobia-related disorders, with its development intersecting psychology, human-computer interaction, and digital health. Early clinical trials (e.g., Rothbaum et al., 1995; Wiederhold & Wiederhold, 2000) established the feasibility of using immersive virtual environments to simulate specific phobic stimuli, laying the foundation for integrating VRET into exposure-based cognitive-behavioural therapies. Subsequent meta-analyses (Opris et al., 2012; Carl et al., 2019) reported moderate to large effect sizes, reinforcing VRET's clinical efficacy and parity with traditional exposure methods. More recent studies expanded its use to complex conditions like social anxiety disorder (Anderson et al., 2013), panic disorder (Botella et al., 2007), and agoraphobia (Bouchard et al., 2017), aided by advances in 3D rendering, motion tracking, and multisensory feedback. Research methodologies have varied, encompassing randomized controlled trials, pre-post interventions, and mixed-method designs. However, significant heterogeneity exists in the technologies used ranging from PC-based systems to mobile VR and in outcome measures, with limited adoption of standardized tools like the Beck Anxiety Inventory (BAI) or Fear Questionnaire (FQ) (Parsons & Rizzo, 2008). This variability complicates meta-analytic synthesis and real-world implementation. Despite promising outcomes, persistent limitations include small sample sizes, short follow-up durations, inadequate blinding, and insufficient exploration of ethical concerns such as cybersickness, data privacy, and therapist training. Although AI-driven personalization (e.g., Freeman et al., 2018) represents an emerging trend, its clinical scalability remains under-researched. While prior reviews have primarily focused on efficacy, few have examined the convergence of clinical effectiveness, technological diversity, and ethical implementation in an integrated manner. This review builds on earlier work by adopting a broader, interdisciplinary lens to identify unresolved issues and guide future digital mental health innovations. In doing so, it contributes a structured synthesis of two decades of empirical research, offering a timely reassessment of VRET's potential and its readiness for widespread adoption.

3. Methodology

3.1 Study Design

A systematic review was conducted in accordance with PRISMA guidelines (Fig. 1) to synthesize empirical evidence on the clinical efficacy, technological progression, and implementation challenges of Virtual Reality Exposure Therapy (VRET) for anxiety and phobia-related disorders. The review focused on peer-reviewed quantitative studies evaluating treatment outcomes of VRET interventions.

3.2 Data Sources and Search Strategy

A comprehensive literature search was conducted across PubMed, PsycINFO, Scopus, and Web of Science for studies published between January 2005 and March 2025. The search terms combined subject headings and keywords such as: "virtual reality," "exposure therapy," "VRET," "anxiety disorders," "phobia," "clinical trial," and "treatment outcome."

3.3 Inclusion and Exclusion Criteria

Studies were selected based on the following inclusion criteria:

- Use of VRET as a primary intervention.
- Target population diagnosed with anxiety or phobia-related disorders.
- Quantitative reporting of treatment outcomes.
- Peer-reviewed, empirical research published in English.

Exclusion criteria included:

- Studies with non-clinical or experimental healthy populations.
- Reviews, editorials, theoretical papers, or qualitative-only studies.
- Studies lacking pre- and post-intervention outcome data.

3.4 Study Selection Process

After removing duplicates, titles and abstracts were independently screened by reviewer. Full texts were reviewed to determine final eligibility. Discrepancies were resolved through discussion or consultation with the reviewer. A total of 38 studies, predominantly randomized controlled trials (RCTs), were included in the final analysis. Figure 1 depicts the PRISMA flowchart detailing study identification, screening, eligibility, and inclusion.

3.5 Data Extraction and Management

A standardized extraction form was used in Microsoft Excel to collect data on author/year, sample characteristics, disorder type, VR hardware/software, study design, outcome measures, reported effect sizes, and limitations. Extraction was performed independently by one reviewer and cross-verified by another.

3.6 Data Analysis

Due to heterogeneity in study designs, VR systems, and outcome assessments, a narrative synthesis approach was adopted. Cohen's *d* was calculated to estimate effect sizes for symptom reduction. Where effect sizes (Cohen's *d*) were not reported, they were calculated using means and standard deviations from pre- and post-intervention scores. In cases where only *t*-values or *p*-values were available, established formulas were applied. When multiple outcomes were reported, primary anxiety measures were prioritized, and values were averaged. Effect sizes were unweighted, given the heterogeneity of study designs and measures. Studies were grouped by disorder type (e.g., social anxiety, agoraphobia) to identify condition-specific patterns.

3.7 Methodological Challenges

The reviewed studies were limited by small, heterogeneous samples, inconsistent follow-up periods, lack of blinding, variability in VR platforms and protocols, and inadequate reporting of adverse effects such as cybersickness, reducing generalizability and comparability. To address this, our review applied strict inclusion criteria, standardized data extraction methods, and clear categorization of VR systems and protocols, enabling more consistent synthesis and interpretation of findings.

3.8 Ethical Considerations

As a secondary analysis of published data, ethical approval was not required. However, ethical concerns related to VRET itself such as privacy, immersion risks, and algorithmic bias were acknowledged and discussed in the review.




Figure 1: PRISMA Chart for systematic review

4. Result Discussion

A total of 38 empirical studies were included in the final analysis, with the majority employing randomized controlled trial (RCT) designs. The studies covered a range of anxiety and phobia-related disorders including acrophobia, social anxiety, agoraphobia, panic disorder, and specific phobias such as fear of flying and animals. Sample sizes ranged from 25 to 98 participants. Virtual reality platforms varied considerably across studies, including PC-based VR systems, smartphone VR, immersive headsets (e.g., Oculus Rift, HTC Vive), and AI-enabled environments.

4.1 Summary of Main Findings

Table 1 summarizes the main findings, including effect sizes and notable benefits by disorder type. Quantitative synthesis revealed moderate to large treatment effects for VRET interventions across multiple anxiety conditions. Reported Cohen's *d* values ranged from 0.60 to 1.15, indicating significant reductions in symptom severity from pre- to post-intervention. Studies consistently reported high levels of patient engagement, improved therapeutic compliance, and lower dropout rates compared to traditional in vivo exposure therapy.

Table 1: Representing summary of main findings from the systematic review

Disorder Type	No. Studies	of No. Participants(n)	of Mean Effect Size (Cohen's d)	Notable Benefits
---------------	-------------	------------------------	---------------------------------	------------------

Acrophobia	8	397	0.90	High immersion, reduced avoidance
Social Anxiety	11	672	0.94	Public speaking, interpersonal skills
Agoraphobia	7	255	0.83	Enhanced mobility, daily functioning
Panic Disorder	4	346	0.88	Heart rate control, fewer attacks
Specific Phobias	8	263	0.78	Animal fear, flying, medical anxiety

Table 1. Summary of main findings from the systematic review, including disorder type, number of studies, mean effect size (Cohen’s *d*), notable benefits, and total participants. Effect sizes are unweighted averages across included studies.

4.2 Interpretation of Findings

These findings support the clinical efficacy of VRET across a broad spectrum of anxiety-related disorders. Figure 2 depicts the Forest plot of mean effect sizes (Cohen’s *d*) for VRET across five disorder types, with 95% confidence intervals and participant counts. The plot highlights conditions where VRET shows the strongest impact while indicating the precision of the evidence. VRET outcomes were frequently comparable to, and occasionally surpassed, those of traditional exposure therapies. The immersive nature of VR enabled more realistic and controlled exposure scenarios, which may account for increased patient engagement and lower attrition. Technological progression was evident in newer studies incorporating AI-driven personalization, biometric feedback, and culturally adaptive avatars. These enhancements were associated with improved therapeutic outcomes and greater patient satisfaction. However, significant heterogeneity was observed in VR hardware/software, exposure durations, and outcome measures. This variability complicates cross-study comparisons and underscores the need for standardized therapeutic frameworks.




Figure 2. Forest plot of mean effect sizes (Cohen’s *d*) for VRET across disorder types

4.3 Comparison with Previous Literature

Our findings align with earlier meta-analyses (e.g., Carl et al., 2019; Opris et al., 2012) reporting moderate-to-large effect sizes for VRET. Unlike earlier reviews limited to efficacy outcomes, this study integrates a broader scope encompassing technological diversity and ethical challenges. To our knowledge, this is the first systematic review to synthesize VRET research up to 2025 while incorporating an ethical-techno-clinical framework. The

continued trend toward positive outcomes reinforces VRET's potential, while emerging concerns highlight the growing complexity of its implementation.

4.4 Study limitation and challenges

Despite promising results, several methodological limitations were prevalent across studies:

- Small and heterogeneous samples in many trials
- Short or inconsistent follow-up durations
- Lack of standardization in outcome measures
- Limited reporting on adverse effects (e.g., cybersickness)
- Insufficient blinding and allocation concealment
- These limitations reduce the generalizability of findings and point to the need for more rigorous, large-scale studies.

4.5 Ethical and Practical Implications

Ethical considerations remain underreported in many studies. Issues such as user data privacy, immersive intensity, and algorithmic bias in AI-enhanced systems require greater scrutiny. For instance, in clinical settings, data privacy concerns may deter use in telehealth-based VRET. Cybersickness can limit session length or require adaptive hardware, particularly in individuals with vestibular disorders. Algorithmic bias in AI-personalized environments could unintentionally reinforce stereotypes, highlighting the need for clinician oversight in automated scenario adjustments. Overall, VRET shows strong potential as a scalable, immersive, and clinically effective tool for anxiety and phobia-related disorders. With ongoing technological advancements and interdisciplinary collaboration, it may soon become a central component of digital mental health interventions.

4.6 Future Directions

Standardized therapeutic frameworks should involve cross-institutional collaborations, integrating clinical guidelines with technology benchmarks (e.g., latency thresholds, immersion scales). AI-driven personalization could adapt exposure scenarios in real-time based on biometric feedback, but requires open-source model validation to ensure transparency and bias mitigation. Partnerships between academia, healthcare providers, and VR developers will be critical for creating scalable, low-cost interventions accessible in both urban and rural contexts.

5. Conclusion

This systematic review highlights the growing clinical relevance of Virtual Reality Exposure Therapy (VRET) in addressing anxiety and phobia-related disorders. The key findings demonstrate that VRET is associated with moderate to large reductions in symptom severity, high patient engagement, and improved therapeutic adherence. These results directly align with the study's objectives of evaluating clinical efficacy, technological diversity, and implementation challenges. By synthesizing research spanning two decades, this study contributes to the interdisciplinary understanding of digital mental health interventions. It also sheds light on the evolving integration of advanced VR technologies, including AI and biometrics, which have the potential to enhance personalization and scalability. However, significant methodological and ethical limitations persist, particularly regarding standardization, long-term efficacy, and access equity. Future research should focus on developing robust, standardized, and ethically sound VRET protocols, while also exploring strategies to ensure broader accessibility and clinical adoption. Overall, this review reinforces the transformative potential of VRET and its role in shaping the future of immersive, technology-enabled mental health care.

Acknowledgement

We the authors, gratefully acknowledge the contributions of the researchers and clinicians whose studies formed the foundation of this review. We would also like to thank the library staff at our institution for providing access to key databases and resources necessary for this study. Special thanks to the academic mentor (Co-Author) who provided valuable feedback during the development of this manuscript and helped as reviewer of the studies. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

- Anderson, P. L., Price, M., Edwards, S. M., Obasaju, M. A., Schmertz, S. K., Zimand, E., & Calamaras, M. R. (2013). Virtual reality exposure therapy for social anxiety disorder: A randomized controlled trial. *Journal of Consulting and Clinical Psychology, 81*(5), 751–760. <https://doi.org/10.1037/a0033559>
- Botella, C., Baños, R. M., Villa, H., Perpiñá, C., & García-Palacios, A. (2007). Virtual reality in the treatment of panic disorder and agoraphobia: A controlled study. *Clinical Psychology & Psychotherapy, 14*(3), 164–175. <https://doi.org/10.1002/cpp.524>
- Bouchard, S., Dumoulin, S., Robillard, G., Guitard, T., Klinger, É., Forget, H., Loranger, C., & Roucalt, F. X. (2017). A randomized control trial for the use of in virtuo exposure in the treatment of panic disorder with agoraphobia. *Cyberpsychology, Behavior, and Social Networking, 20*(4), 256–264. <https://doi.org/10.1089/cyber.2016.0559>
- Carl, E., Stein, A. T., Levihn-Coon, A., Pogue, J. R., Rothbaum, B., Emmelkamp, P., & Powers, M. B. (2019). Virtual reality exposure therapy for anxiety and related disorders: A meta-analysis of randomized controlled trials. *Journal of Anxiety Disorders, 61*, 27–36. <https://doi.org/10.1016/j.janxdis.2018.08.003>
- Emmelkamp, P. M. G., & Meyerbröker, K. (2020). Virtual reality therapy in mental health. *Annual Review of Clinical Psychology, 16*, 495–519. <https://doi.org/10.1146/annurev-clinpsy-071519-113654>
- Freeman, D., Reeve, S., Robinson, A., Ehlers, A., Clark, D., Spanlang, B., & Slater, M. (2018). Virtual reality in the assessment, understanding, and treatment of mental health disorders. *Psychological Medicine, 47*(14), 2393–2400. <https://doi.org/10.1017/S003329171700040X>
- Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Archives of General Psychiatry, 62*(6), 593–602. <https://doi.org/10.1001/archpsyc.62.6.593>
- Maples-Keller, J. L., Bunnell, B. E., Kim, S. J., & Rothbaum, B. O. (2017). The use of virtual reality technology in the treatment of anxiety and other psychiatric disorders. *Harvard Review of Psychiatry, 25*(3), 103–113. <https://doi.org/10.1097/HRP.000000000000138>
- Opris, D., Pinte, S., García-Palacios, A., Botella, C., Szamosközi, S., & David, D. (2012). Virtual reality exposure therapy in anxiety disorders: A quantitative meta-analysis. *Depression and Anxiety, 29*(2), 85–93. <https://doi.org/10.1002/da.20910>
- Parsons, T. D., & Rizzo, A. A. (2008). Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: A meta-analysis. *Journal of Behavior Therapy and Experimental Psychiatry, 39*(3), 250–261. <https://doi.org/10.1016/j.jbtep.2007.07.007>

- Rothbaum, B. O., Hodges, L., Kooper, R., & Opdyke, D. (1995). Virtual reality graded exposure in the treatment of acrophobia: A case report. *Behavior Therapy*, 26(3), 547–554. [https://doi.org/10.1016/S0005-7894\(05\)80099-5](https://doi.org/10.1016/S0005-7894(05)80099-5)
- Wiederhold, B. K., & Wiederhold, M. D. (2000). Cybertherapy for fear of flying: State of the art. *CyberPsychology & Behavior*, 3(5), 693–697. <https://doi.org/10.1089/10949310050191865>
- Wiederhold, B. K., & Wiederhold, M. D. (2020). The future of cybertherapy: Improved access, reduced costs, and better outcomes. *CyberPsychology, Behavior, and Social Networking*, 23(2), 73–75. <https://doi.org/10.1089/cyber.2019.29162.bkw>
- World Health Organization (WHO). (2022). *World mental health report: Transforming mental health for all*. <https://www.who.int/publications/i/item/9789240049338>